Archives

Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy​Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy 

People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according to a brief report published online Feb. 12 in JAMA Ophthalmology. ​People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior Read More

STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding  ​STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding   

In the last year and a half, direct-to-consumer telehealth company Hims & Hers has become a leading voice in the debate over compounded GLP-1 weight loss medications. On Monday, it announced earnings from the last quarter of 2025 after a whirlwind month that raised questions about the regulatory risks of the company’s compounding model and Read More

Bariatric Surgery and GLP-1 Drugs Both Support Sustained Fat Loss​Bariatric Surgery and GLP-1 Drugs Both Support Sustained Fat Loss 

Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in a clinical setting. ​Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in Read More

FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications​FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications 

The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists. ​The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists. 

Study finds bariatric surgery outperforms medical therapy for T2D across income levels​Study finds bariatric surgery outperforms medical therapy for T2D across income levels 

Nonmedical factors drive up to 60 percent of health outcomes, and for people with type 2 diabetes (T2D), social determinants of health factors like poverty, food insecurity, and unstable housing can derail even the best treatment plans. Now, a long-term study led by investigators at Joslin Diabetes Center finds that bariatric metabolic surgery is more effective at glycemic and weight control than medical and lifestyle interventions for people with T2D, even in the setting of social vulnerability. The work is published in the journal Annals of Internal Medicine.